Protein tyrosine phosphatases regulating JAK2-STAT3 signaling (PTPs (JAK2-STAT3))

Protein tyrosine phosphatases (PTPs) that regulate the JAK2-STAT3 signaling pathway are a functional class of enzymes responsible for the negative regulation of cytokine and growth factor signaling. Key members of this group include PTPN1 (PTP1B), PTPN2 (TCPTP), PTPN6 (SHP-1), and PTPN11 (SHP-2), which dephosphorylate Janus kinase 2 (JAK2) and Signal Transducer and Activator of Transcription 3 (STAT3) to terminate signal transduction (Xu & Qu, 2008; Loh et al., 2011). In many cancers, these phosphatases are either inactivated (e.g., PTPRT, PTPRD) or overexpressed/mutated (e.g., SHP-2), leading to constitutive activation of the JAK2-STAT3 axis, which promotes cell survival, proliferation, and immune evasion (Veeriah et al., 2009). Conversely, in metabolic diseases like diabetes and obesity, PTP1B acts as a negative regulator of insulin and leptin signaling, making its inhibition a therapeutic strategy (Zabolotny et al., 2002). Drug development efforts focus on small-molecule inhibitors, particularly for SHP-2 and PTP1B, though the high structural homology among PTP active sites poses significant challenges for selectivity and bioavailability (Zhang, 2017).

Other names

JAK2-STAT3 phosphatasesPTPN1PTPN2PTPN6PTPN11PTPRTPTPRDNegative regulators of JAK-STAT signaling

Small molecule inhibition of specific protein tyrosine phosphatases to either enhance signaling (e.g., insulin/leptin signaling via PTP1B inhibition) or disrupt oncogenic signaling complexes (e.g., SHP2 inhibition in RAS-driven cancers).